nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients

BACKGROUND: In the NAPOLI‐1 phase 3 trial, liposomal irinotecan (nal‐IRI) +5‐fluorouracil/leucovorin (5‐FU/LV) significantly increased mPFS versus 5‐FU/LV (3.1 vs. 1.5 months [unstratified HR = 0.56, p = 0.0001]) in patients with mPAC that progressed on prior gemcitabine‐based therapy. This randomiz...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Med
Egile Nagusiak: Ueno, Makoto, Nakamori, Shoji, Sugimori, Kazuya, Kanai, Masashi, Ikeda, Masafumi, Ozaka, Masato, Furukawa, Masayuki, Okusaka, Takuji, Kawabe, Ken, Furuse, Junji, Komatsu, Yoshito, Ishii, Hiroshi, Sato, Atsushi, Shimizu, Satoshi, Chugh, Priti, Tang, Rui, Ioka, Tatsuya
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Clinical Cancer Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7774735/
https://ncbi.nlm.nih.gov/pubmed/33099898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3558
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak